A report from the Children’s Oncology Group found that 5-year overall survival was lower in ARMS cases with PAX3::FOXO1 fusions (64%) or PAX7::FOXO1 fusions (87%) than in fusion-negative ARMS (89%) [158]. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.